Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer

Fig. 4

In vitro GCNT3 specific inhibition suppressed mucins deposition promoting T cells infiltration. a Immunostaining analysis for GCNT3, MUC1 and MUC5AC. Protein analyzed (in red) and nuclei (in blue) were reported. Images shown are representative of 1–2 out of more than 10 of the 3D cancer cultures acquired. 100X and 200X magnification were reported. b Boxplot showing normalized RNA-seq counts for Tert gene in 13KC and KPC06 models. c In vitro recognition platform between Telomerase specific T cells and 3D-pancreatic cancer cultures from 13 KC and KPC06 mouse model. T cells are stained with CMPTX (red) and Caspase 3/7 activity is shown in green. d In vitro recognition platform between patient derived organoids (PDO) and T cells isolated from the same patient. T cells are stained with CMPTX (red) and Caspase 3/7 activity is shown in green. e Barplot showing the fold increase in Caspase 3/7 activity in comparison to control (CTR). The fold increase is calculated as the ratio between the mean of Corrected Total Fluorescence (CTCF) quantified in each group and the mean of control. ****Pvalue < 0.0001, *Pvalue < 0.05. f Barplot showing the expression of Interferon γ in pg/ml assessed by ELISA in the conditioned medium from each condition of the interaction platform. ****Pvalue < 0.0001

Back to article page